Eyeing the booming renal therapeutics market, Swiss pharmaceutical giant Novartis AG plans to spend up to $3.5 billion on Chinook Therapeutics. The deal marks the latest in a string of high-profile mergers and acquisition (M&A) deals in the pharma sector over the past roughly half year.Chinook’s kidney disease specialization in the Novartis M&A equation
At the heart of the deal is Chinook’s specialization in precision medicines for kidney disease.
The rising prevalence of chronic kidney disease, which affects roughly 10% of the global population, according to the National Kidney Foundation, underscores the urgency of addressing renal disorders.
The growing prevalence of diabetes, a core contributor to the rise of renal disorders, has stimulated the market for therapies for chronic kidney disease.